UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1436-3
Program Prior Authorization/Notification
Medication *Entyvio® (vedolizumab)
*This program applies to the subcutaneous formulation of vedolizumab
P&T Approval Date 4/2024, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Entyvio (vedolizumab) for subcutaneous use is an integrin receptor antagonist indicated in adults
for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease
(CD).
2. Coverage Criteriaa:
A. Ulcerative Colitis
1. Initial Authorization
a. Entyvio for subcutaneous use will be approved based on both of the following
criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) Patient is not receiving Entyvio in combination with a targeted
immunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq
(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya
(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Ustekinumab, Zeposia
(ozanimod)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Entyvio for subcutaneous use will be approved based on both of the following
criteria:
(1) Documentation of positive clinical response to Entyvio therapy
-AND-
(2) Patient is not receiving Entyvio in combination with a targeted
immunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq
(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya
(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Ustekinumab, Zeposia
© 2025 UnitedHealthcare Services, Inc.
1
(ozanimod)]
Authorization will be issued for 12 months.
B. Crohn’s Disease
1. Initial Authorization
a. Entyvio for subcutaneous use will be approved based on both of the following
criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) Patient is not receiving Entyvio in combination with a targeted
immunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq
(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya
(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Ustekinumab, Zeposia
(ozanimod)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Entyvio for subcutaneous use will be approved based on both of the following
criteria:
(1) Documentation of positive clinical response to Entyvio therapy
-AND-
(2) Patient is not receiving Entyvio in combination with a targeted
immunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq
(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya
(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Ustekinumab, Zeposia
(ozanimod)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
© 2025 UnitedHealthcare Services, Inc.
2
• Supply limits may be in place.
4. References:
1. Entyvio [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; April 2024.
Program Prior Authorization/Notification – Entyvio (vedolizumab)
Change Control
4/2024 New program.
5/2024 Added coverage criteria for Crohn’s disease. Updated background and
reference.
5/2025 Annual review with no change to coverage criteria. Updated example
with no change to clinical intent.
© 2025 UnitedHealthcare Services, Inc.
3